Hereditary demyelinating neuropathy of infancy
A genetically complex syndrome

J. Tyson,1 D. Ellis,1 U. Fairbrother,1 R. H. M. King,2 F. Muntoni,3 J. Jacobs,5 S. Malcolm,1 A. E. Harding4,† and P. K. Thomas2,4

1Molecular Genetics Unit, Institute of Child Health, Correspondence to: Professor P. K. Thomas, Department of Clinical Neurosciences, Royal Free Hospital School of Medicine, 2Department of Paediatrics, Royal Postgraduate Medical School and Departments of 4Clinical Neurology and 5Neuropathology, Institute of Neurology, London, UK
†Deceased

Summary
Nine cases are described of a demyelinating peripheral neuropathy that had an onset in infancy. The clinical features conformed to those of type III hereditary motor and sensory neuropathy or Dejerine–Sottas disease. All showed a severe neurological deficit and had profoundly reduced nerve conduction velocities. Amongst these cases we identified four novel point mutations in the peripheral myelin protein 22 (PMP22) gene. These were Ser72Trp, Ser76Ile and Leu80Pro. The Ser72Trp mutation was dominantly inherited for the PMP22 and P0 genes and nerve biopsy are therefore merited in patients with a childhood demyelinating neuropathy with focally folded myelin sheaths. One showed both bulbar and diaphragmatic involvement. It is concluded that hereditary demyelinating neuropathy of infancy is genetically heterogeneous. Mutational screening for the PMP22 and P0 genes and nerve biopsy are therefore merited in patients with a childhood demyelinating neuropathy that is more severe than usual and in whom a chromosome 17 duplication is not present.

Keywords: hereditary motor and sensory neuropathy; demyelination; peripheral myelin protein 22; myelin protein zero

Abbreviations: HNFFM = hereditary neuropathy with focally folded myelin sheaths; HNPP = hereditary neuropathy with liability to pressure palsies; HMSN = hereditary motor and sensory neuropathy; MNCV = motor nerve conduction velocity; PCR = polymerase chain reaction; PMP22 = peripheral myelin protein 22; P0 = P zero myelin protein; SSCP = single stranded confirmation of polymorphism

Introduction
The current classification of the hereditary motor and sensory neuropathies largely had its origins in the study by Dyck and Lambert (1968a, b) in which the syndrome of peroneal muscular atrophy was subdivided, on the basis of combined clinical, genetic, electrophysiological and nerve biopsy findings into two broad categories. The first consisted of demyelinating neuropathies and was itself subdivided into hypertrophic neuropathy of the Charcot–Marie–Tooth type, usually with autosomal dominant inheritance, and a more severe type with presumed autosomal recessive inheritance referred to as hypertrophic neuropathy of infancy or Dejerine–Sottas disease. The second category comprised the neuronal type of peroneal muscular atrophy. The nonspecific term hereditary motor and sensory neuropathy (HMSN) was introduced by Thomas et al. (1974) to cover this group of conditions. It broadly, but not precisely, encompasses both Charcot–Marie–Tooth disease and Dejerine–Sottas disease as employed in the gene mapping literature. In the study by Dyck and Lambert (1968a, b) and that by Harding and Thomas (1980a, b), cases with X-linked inheritance were not identified but these were recognized later (see Hahn, 1993). The more benign form of demyelinating HMSN was
categorized as HMSN I and both autosomal dominant and, less commonly, autosomal recessive, families were described (Harding and Thomas, 1980b, c). The severe childhood form was termed HMSN III by Dyck (1975), although it was later pointed out that there are difficulties in distinguishing between HMSN III and autosomal recessive HMSN I (Ouvrier et al., 1987).

Molecular genetic studies have demonstrated that the majority of patients with autosomal dominant HMSN I have a large (1.5 Mb) duplication on the short arm of chromosome 17 (17p11.2) which results in affected individuals carrying three copies in this region instead of the normal two (Lupski et al., 1991; Raeymakers et al., 1991). Evidence that the disorder, referred to as HMSN Ia (Charcot–Marie–Tooth disease type 1A), results from a dosage effect, rather than a disruption of a gene during duplication, was obtained from the observation that a more severe phenotype was shown by a patient whose parents both carried the duplication and he himself carried four copies (Lupski et al., 1991). Secondly, a small number of patients have been reported who carry a much larger, cytogenetically visible, duplication or translocation, with breakpoints well outside the critical region and who still show signs of HMSN Ia (Chance et al., 1992; Lupski et al., 1992; Upadhyaya et al., 1993). The initial evidence that the gene for a myelin protein (PMP22) could be the responsible gene within the duplication came from observations on a mouse model for demyelinating neuropathy, the Trembler mouse. Point mutations within the PMP22 gene were found in two allelic Trembler mutants, Tr and Tr-J (Suter et al., 1992a, b). Confirmation of the pathogenetic role of PMP22 came from a family in which affected individuals carried the same mutation as the Tr-J mouse (Valentijn et al., 1992). However, the overexpression of mRNA for peripheral myelin protein 22 (PMP22) was found to be increased in only ~50% of nerve biopsies from patients with HMSN Ia (Hanemann et al., 1994; Yoshikawa et al., 1994).

HMSN Ia is a relatively benign condition most commonly with an onset in the first or second decades, and shows progression throughout adult life. Other families with the HMSN I phenotype have been shown to be due to mutations in the \( P_0 \) (P zero myelin protein) gene (Kulkens et al., 1993; Su et al., 1993) on chromosome 1q22–23 (Hayasaka et al., 1993a). This disorder has been categorized as HMSN Ib (Charcot–Marie–Tooth disease type 1B). The severe HMSN III phenotype has recently been shown to consist of more than one entity. Some cases are probably nongenetic and examples of chronic inflammatory demyelinating polyneuropathy (Gabreëls-Festen and Gabreëls, 1993). Others have been shown to be due to de novo mutations of the PMP22 (Roa et al., 1993a) or \( P_0 \) (Hayasaka et al., 1993b) genes. They have been referred to as Dejerine–Sottas disease A and B, respectively, in the gene mapping literature. The present study documents a group of nine patients with the HMSN III phenotype in which the onset was in early childhood and in whom the disorder led to severe disability.

**Case reports**

**Case 1 (9937)**

Female aged 39 years. There was no family history of neurological disorder and her parents were not consanguinous. Her pregnancy and birth were normal but she was observed to be hypotonic at the age of 1 month. Her early motor milestones were delayed. She did not walk until aged 5 years. Slow deterioration of motor function in all four limbs subsequently occurred, but she is still able to walk for short distances with elbow crutches. Increasing weakness of her hands became apparent over the past 7–8 years, but manual function was improved by bilateral tendon transfer operations to improve thumb opposition. She has been aware of distal sensory loss in the upper and lower limbs and has to guide hand movement by vision. Hearing has been impaired for ~10 years.

**Examination**

The cranial nerves were normal apart from bilateral mild facial weakness and moderate sensorineural deafness. There was mild weakness of neck flexion, distal wasting in the upper limbs, with weakness of all muscle groups below the elbows and severe weakness of the small hand muscles. She showed a mild postural tremor and upper limb ataxia. In the lower limbs there was generalized wasting and weakness with total muscle paralysis below the knees. All tendon reflexes were absent and no plantar responses were obtainable. All sensory modalities were impaired both in the lower and upper limbs. Her peripheral nerves were not thickened.

**Investigations**

Haematological and biochemical screening were normal, including serum lipids, phytic acid and white cell enzymes, as was the CSF. Ulnar motor nerve conduction velocity (MNCV) was 3 m/s (1963). Neuro-otological testing in 1971 revealed bilaterally absent caloric responses and normal audiometry. When repeated in 1985, bilateral high-tone deafness was present. Brainstem auditory evoked potentials were poorly reproducible and wave V was delayed bilaterally. Speech discrimination scores were severely reduced. Evoked otocoustic responses were not obtained from either ear. Sural nerve biopsy was performed in 1963 (see Results).

**Case 2 (12868)**

Female aged 21 years. The pregnancy and birth were normal. She did not walk until the age of 2 years. She was always unsteady on her feet and was never able to run. Scoliosis developed at the age of 12 years and spinal fusion was performed at 14 years. By the age of 16 years she required support to walk and she had developed distal upper limb...
weakness. When seen at age 21 years her condition had stabilized.

**Examination**
Apart from mild weakness of eye closure, the cranial nerves were normal. There was diffuse wasting and weakness in all four limbs. Her tendon reflexes were all absent and her plantar responses flexor. She showed impairment for all sensory modalities distally in the limbs. There was a prominent kyphoscoliosis and mild bilateral pes cavus. There was no definite nerve thickening.

**Investigations**
Haematological and biochemical screening, including serum lipids and phytanic acid, and white cell enzymes, was normal, as were cranial and spinal MRIs and an ECG. Electromyography demonstrated denervation. Motor nerves were all inexcitable, even at high stimulus strengths, and sensory nerve action potentials were unrecordable. Sural nerve biopsy was performed (see Results).

**Family history**
12868’s parents, who were nonconsanguinous, were asymptomatic and normal on neurological examination. She had a twin brother and an older sister who were healthy and a son (Case 3) who is affected.

**Case 3 (13533)**
Male aged 3 years, son of Case 2. He did not sit unsupported until after age 1 year and was still not walking at age 3 years. Weakness, maximal distally was evident in all four limbs, and greater in the legs. He was areflexic and showed no skeletal deformity. The peripheral nerves were not thickened.

**Case 4 (12687)**
Female aged 28 years. The pregnancy and birth were normal. She was hypotonic at birth, sat unsupported at 18–20 months and did not walk until 3–4 years. Her gait was always unsteady and she was never able to run. Progressive deterioration occurred and she became unable to walk when aged 11 years. Weakness of her upper limbs had also been present throughout her life. Foot deformity and kyphoscoliosis developed during childhood. The patient was adopted and no family history was available.

**Examination**
There was mild weakness of eye closure but otherwise cranial nerve function was normal. She showed diffuse muscle wasting and weakness in the upper limbs which was severe distally and greater on the left where her fingers were clawed.

Her cough was weak, as was her diaphragm, with paradoxical abdominal wall movement on breathing. There was diffuse wasting in the legs with no voluntary movement. She was areflexic; plantar responses were unobtainable. All sensory modalities were impaired distally in the limbs. There was severe kyphoscoliosis and bilateral equinovarus foot deformities. Her peripheral nerves were possibly thickened.

**Investigations**
Haematological and biochemical screening was negative. Her peripheral nerves could not be stimulated at high stimulus strengths. Her vital capacity fell from 2.5 l when sitting to 1.5 l on lying. A sleep study showed normal blood gas values. Spinal MRI demonstrated diffuse thickening of nerve roots, particularly in the cervical region.

**Case 5 (12274)**
Female aged 6 years. The pregnancy and birth were normal. She did not walk until aged 2 years. She currently has difficulty in walking for long distances and falls readily. She can run in an ungainly manner. Upper limb function has been satisfactory. The patient’s parents were healthy and nonconsanguinous with no abnormality on neurological examination and normal nerve conduction. She had two healthy older siblings.

**Examination**
The cranial nerves were normal. Her limbs were hypotonic. Upper limb motor function was normal but there was diffuse lower limb weakness. The tendon reflexes were all absent and her plantar responses were flexor. There was no detectable sensory deficit. She showed an excessive lumbar lordosis but there was no other skeletal abnormality and her peripheral nerves were not enlarged.

**Investigations**
Ulnar MNCV was 8 m/s. No response was obtained from the peroneal nerve.

**Case 6 (14257)**
Female aged 25 years. Her developmental motor milestones were delayed. When first assessed neurologically at the age of 21 years, she had weakness in all four limbs, generalized tendon areflexia and flexor plantar responses. Corrective operations for foot drop were performed during childhood. Progressive deterioration subsequently occurred so that currently she is confined to a wheelchair and has considerable difficulty with her upper limbs. The patient’s parents were healthy and nonconsanguinous.
**Examination**

The cranial nerves were normal. There was generalized wasting and weakness in the limbs, maximal distally and greater in the lower than in the upper limbs. Her tendon reflexes were absent and the plantar responses were flexor. There was sensory loss below both knees. She had no foot deformity.

**Investigations**

Electromyography demonstrated widespread denervation in lower and upper limb muscles. Ulnar MNCV was 3 m/s; no values were obtained for the lower limbs. Upper and lower limb sensory action potentials were absent. An EEG, cranial CT scan and an ECG were normal.

**Case 8 (10994)**

Male aged 5 years. The pregnancy and birth were normal. He began to walk when aged 1 year, but unsteadily. He progressively developed a bilateral dropfoot gait. His hands had been noted to be clumsy and his fingers to be held in a flexed posture. His speech was slightly indistinct. The patient’s parents were healthy and normal on neurological examination, but were consanguinous (first cousins). He had an older brother aged 10 years, who was normal, but had been diagnosed as having vitamin D deficiency in early childhood.

**Case 7 (12692)**

Female aged 42 years, product of a consanguinous (father/daughter) relationship. Her birth and early development were normal. When aged 2.5 years her left foot became ‘floppy’ and inverted on walking. A corrective operation was performed without benefit. Progressive deterioration occurred with the development of distal weakness and wasting in all limbs associated with tendon areflexia. Callipers for walking were provided at the age of 12 years. Progressive deterioration continued with increasing weakness and distal sensory loss in the limbs. Scoliosis developed during early adolescence and mild bilateral deafness at the age of 35 years. She has been confined to a wheelchair for the past 12 years. Her parents were stated to have been normal as is a daughter of the patient. Her sister, by the same parentage, is mentally retarded but shows no evidence of neuropathy on examination and has normal motor and sensory nerve conduction.

**Examination**

On neurological examination, the cranial nerves were normal apart from bilateral sensorineural deafness. There was diffuse severe wasting in all four limbs, total tendon areflexia and unobtainable plantar responses. She showed a distally accentuated loss for all sensory modalities both in the arms and legs. Her peripheral nerves were not enlarged. Examination of other systems revealed bilateral xanthelasmata and a severe kyphoscoliosis.

**Investigations**

Haematological and biochemical screening was normal, including serum lipids, phytic acid and vitamin E levels. White cell enzyme screening showed pseudodeficiency for aryl sulphatase A (homozygous for PD allele). Hexosaminidase and β-galactosidase activity was normal. Electromyography demonstrated widespread denervation in lower and upper limb muscles. Ulnar MNCV was 3 m/s; no values were obtained for the lower limbs. Upper and lower limb sensory action potentials were absent. An EEG, cranial CT scan and an ECG were normal.

**Case 9 (14324)**

Male aged 16 years. He was born by a high forceps delivery following prolonged labour. His mother noticed that he had an abnormal cry as a baby. His early developmental milestones were not delayed. He sat unsupported at 6 months. He walked at 13 months, but it was noticed that if he fell he was ‘reluctant’ to get up. Problems with walking soon became evident and he was referred to the Hammersmith Hospital at the age of 3 years when his limbs were noted to be thin and hypotonic and no tendon reflexes were elicitable. Shortly
Hereditary demyelinating neuropathy of infancy

was generalized wasting and weakness in the limbs with total paralysis below the knees. His tendon reflexes were all absent and no plantar responses were obtainable. Pain appreciation was impaired distally in all four limbs. Vibration sense was lost in his feet and joint position sense impaired in his toes. There were bilateral flexion contractures of his fingers, but no other skeletal deformity. His peripheral nerves were not thickened.

Investigations

Haematological and biochemical screening was negative, including serum lipids, phytic acid and vitamin E concentrations. Ulnar MNCV, when aged 5 years was 16 m/s. In a recent study, the small hand and foot muscles were found to be totally denervated. No evoked response was obtained from flexor carpi ulnaris even at very high stimulus strengths despite preservation of some voluntary motor unit activity. Upper and lower limb sensory action potentials were absent. Sural nerve biopsy was performed (see Results).

Methods

Molecular genetic studies

Testing for the 1.5 Mb duplication on chromosome 17p11.2 was performed as described previously (Hallam et al., 1992; Hensels et al., 1993; Chance et al., 1994).

Sequencing and single stranded confirmation of polymorphism (SSCP)

PMP22 gene sequences were amplified from genomic DNA using the following primers. Exon 1: forward 5'AGAA-ACTCCGCTGAGCAGAA3' (from the 5' untranslated sequence), reverse 5'GGAACCCAGATGGGGAG3' (from intron 1). Exon 2: forward TTTCTTCACTCTCCCTCC3' reverse 5'GTCTGAGGACACGTCAGG3'. Exon 3: forward 5'TGGCCAGCTCTCCTAAC3', reverse 5'CACC-CGCTCCACATG3'. Exon 4: forward 5'GCCATGGACT-CTCCGTC3', reverse (3' nontranslated) 5'CCTATGTA-CGCTCAGAG3'. Each of the forward primers was bioinylated for sequencing. A nested sequencing primer 5'ATGCTCCATCTTTGCTGAGAT3' was used to sequence the 3' end of the exon 1 product. The size of the polymerase chain reaction (PCR) products was 166 bp (base pairs) (exon 1), 194 bp (exon 2), 220 bp (exon 3) and 250 bp (exon 4).

F₀ primer sequences and nested sequencing primers were as described in Nelis et al. (1994a).

Two methods of SSCP analysis were used. Radioactive products were analysed on 6% polyacrylamide gels containing 5% glycerol and run both at room temperature and at 4°C. Nonradioactive products were analysed on 1×Hydrolink MDE gels (J. T. Baker) at 4°C with and without 8% glycerol. The
gels were stained with 0.012 M silver nitrate for 20 min after initial fixing and oxidizing steps with 10% ethanol for 5 min and 1% nitric acid for 3 min. After developing the bands to optimum intensity with 0.28 M Na2CO3 in 0.019% formaldehyde, the reaction was stopped with 10% acetic acid for 2 min. After a final rinse step with distilled water, the gel was reduced in size with 50% ethanol and dried.

Biotinylated PCR products were purified using Dynabeads (Dynal, UK) and single stranded products sequenced using the USB Sequenase version 2.0 kit. PCR amplified fragments from exon 4 of the P0 gene in Case 6 were cloned using an Invitrogen TA cloning kit. Fifteen individual clones were sequenced. A G→C change at position 1068 within codon 167 followed by a deletion of a C position at position 1071 were initial fixing and oxidizing steps with 10% ethanol for 5 min and 1% nitric acid for 3 min. After developing the bands to optimum intensity with 0.28 M Na2CO3 in 0.019% formaldehyde, the reaction was stopped with 10% acetic acid for 2 min. After a final rinse step with distilled water, the gel was reduced in size with 50% ethanol and dried.

Biotinylated PCR products were purified using Dynabeads (Dynal, UK) and single stranded products sequenced using the USB Sequenase version 2.0 kit. PCR amplified fragments from exon 4 of the P0 gene in Case 6 were cloned using an Invitrogen TA cloning kit. Fifteen individual clones were sequenced. A G→C change at position 1068 within codon 167 followed by a deletion of a C position at position 1071 were found in one strand (Fig. 3). This would result in a frame shift and a highly altered amino acid sequence, but as no new termination codons would be produced, an extended protein (full length plus two amino acids) would be found (Fig. 4). Each sequence change was confirmed by restriction-enzyme digestion of a PCR product amplified from genomic DNA. The deletion of C (1071) destroyed a BsaI site (CCTCGG to TCTCGG) (Fig. 3B) and the G→C change creates an MspI site (Fig. 3C).

**Nerve biopsies**

Sural nerve fascicular biopsies were obtained from a standard retromalleolar site. They were processed by routine techniques using aldehyde fixation, postosmication and dehydration through an ascending alcohol series, followed by resin embedding. Semithin sections were stained with thionin and acridine orange (Sievers, 1971) or with methylene blue, azure II and basic fuchsin (Humphrey and Pittman, 1974) for examination by light microscopy. Ultrathin sections for electron microscopy were contrasted with uranyl acetate and lead citrate.

**Results**

**Molecular genetics**

All nine patients formed part of a study to establish the clinical phenotype associated with the duplication of chromosome 17p11.2 found in patients with HMSN Ia (Marquez et al., 1996). They were selected for sequencing of the PMP22 and P0 genes after it was shown that they did not possess a duplication or deletion.

**PMP22 mutations**

Sequence analysis of all four exons and splice site sequences showed changes resulting in amino acid missense mutations in four patients (Cases 1–4). Cases 2 and 3 are mother and son (Fig. 2). The sequence changes were Ser76Ile, Ser72Trp and Leu80Pro, all in exon 3 (see Table 1). The changes were confirmed by restriction enzyme digestion, as Taq I (Ser72Trp) and Bsm I (Ser76Ile) sites are removed. All three changes were clearly demonstrable using SSCP and no such SSCP change was found in 52 other individuals, indicating that they are not polymorphisms.

**P0 mutations**

A substitution of isoleucine by threonine at position 135, as a result of a T→C change, was observed in Case 5 (Fig. 2D). As a more complex change involving >1 bp was observed in Case 6, the PCR products were cloned and several individual clones sequenced. A G→C change at position 1068 within codon 167 followed by a deletion of a C position at position 1071 were found in one strand (Fig. 3). This would result in a frame shift and a highly altered amino acid sequence, but as no new termination codons would be produced, an extended protein (full length plus two amino acids) would be found (Fig. 4). Each sequence change was confirmed by restriction-enzyme digestion of a PCR product amplified from genomic DNA. The deletion of C (1071) destroyed a BsaI site (CCTCGG to TCTCGG) (Fig. 3B) and the G→C change creates an MspI site (Fig. 3C).

**Cases 7–9**

In these patients the coding sequence for the PMP22 gene was normal and no SSCP or sequence change was found in any of the six exons of P0.

**Nerve biopsies**

**Case 1**

Sural nerve biopsy was performed at the age of 8 years. Only paraffin-embedded material was available. There was a loss of myelinated fibres, surviving fibres possessing uniformly thin myelin sheaths, and excess endoneurial collagenization. No onion bulbs were seen.

**Case 2**

Sural nerve biopsy was performed at the age of 15 years. The specimen consisted of two small fascicles with an area of only 0.22 mm2 (age-matched controls 0.5–0.6 mm2 (Jacobs and Love, 1985). The nerve was largely occupied by onion bulb formations, some having demyelinated or thinly myelinated axons at their centres (Fig. 5). There was increased endoneurial collagen and some oedema. Electron microscopy showed concentrically arranged Schwann cell processes occasionally enclosing an axon (Fig. 6). There was often loss of Schwann cell cytoplasm from the innermost processes leaving paired strands of basement membrane (Figs 5 and 6).

**Case 6**

A vastus medialis muscle biopsy was performed at the age of 3 years. This showed little abnormality apart from mild type II fibre atrophy. Intramuscular nerve bundles were severely abnormal, containing both large and small axons without detectable myelin sheaths. Minor hypertrophic (onion-bulb) change was evident.

**Case 7**

Sural nerve biopsies were performed at the age of 22 and 37 years and a radial nerve biopsy at the age of 39 years. All three showed a reduced myelinated nerve fibre density with
Hereditary demyelinating neuropathy of infancy

Table 1  **Novel mutations in the PMP22 gene**

<table>
<thead>
<tr>
<th>Case</th>
<th>Amino acid</th>
<th>Mutation</th>
<th>Restriction site</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>76</td>
<td>Ser (AGC)→Ile (ATC)</td>
<td>Ban I</td>
</tr>
<tr>
<td>2/3</td>
<td>72</td>
<td>Ser (TG)→Trp (TG)</td>
<td>Taq I</td>
</tr>
<tr>
<td>4</td>
<td>80</td>
<td>Leu (CTG)→Pro (CCG)</td>
<td>None</td>
</tr>
</tbody>
</table>

uniformly thin myelin sheaths around surviving axons (Fig. 7). In transverse sections viewed by light microscopy, myelinated and demyelinated fibres were surrounded by a largely acellular zone of dense collagen, delimited by fibroblasts with encircling processes (Fig. 7). These changes became more evident in the successive biopsies. Staining for metachromatic material was consistently negative. Electron microscopy confirmed these appearances and demonstrated the presence of onion bulbs.
Fig. 3 DNA sequence changes in individual clones (A) and restriction site alterations in PCR products from genomic DNA (B and C) in 14257. (B) *BsaI* digestion of PCR amplified exon 4. Track 1 is a 100 bp ladder; tracks 2 and 6 are from Case 6, tracks 3–5 and 7–9 from normal controls, and track 10 is undigested exon 4 product. The 308 bp product is cut into 166 and 142 bp fragments. The *BsaI* site is shown in bold in the normal sequence. (C) *MspI* digest of PCR amplified exon 4. Track 1 is a 100 bp ladder; tracks 2 and 6 are from Case 6, and tracks 3–5 and 7–9 from normal controls. Track 10 shows undigested exon 4 products. The creation of an *MspI* site is shown in bold in the sequence for Case 6. P = patient; N = normal.

Cases 8 and 9
The biopsy appearances in these two cases were closely similar and they will therefore be described together. The biopsy from Case 8 was obtained at the age of 5 years and that from Case 9 at the age of 16 years. Both specimens showed a severe depletion of myelinated nerve fibres. Fibre density was 3096/ mm² in Case 8 and 910/mm² in Case 9 (normal range for these ages 8000–11 000/mm²; Jacobs and Love, 1985). In transverse sections viewed by light microscopy, the myelin was frequently thrown into highly irregular conformations (Fig. 9A) and measurements of the g ratio (axon diameter/total fibre diameter) showed abnormally high values, indicating hypomyelination. Electron microscopy demonstrated that the myelin irregularity was related to abnormal outpouching of myelin (Fig. 10A and B). In teased fibre preparations and in
Hereditary demyelinating neuropathy of infancy

Wild Type MAPGAPSSSPSPILAVLLFSSLVSPAIAIVVYTDREVHAGVSRVTLLHCSFWSE
Mutant

WVSDDISFTWRYQPEGGRDAISIFHYAKGQPYIDEVGTFKERIQQWVDPRWDGSI

VIHNLDSDNGTFTCDVKNPPDIVKTSQVTLYVFKEVTRYGVVLGAVIGGVGLGVV

LLLLLFVVRWCWLRQAALQRLSAMEKGLHKGKDAKRGQTPVLYAMLDCCCCFSTWFAGTYAGRRPCRGGVLLWRNGCSTQERTRRSAGGRRQCCMQC

HSRSTKAVSEKKAKGLGERSKDKKWTTEAPKLSVRRRPRGWSLRIRNSG*

Fig. 4 The effect on the amino acid sequence of the complex mutation of P0 in patient 14257. The top line shows the normal sequence. Below is the predicted mutated sequence, starting at amino acid 167 and terminating four amino acids beyond the normal termination codon.

Fig. 5 Case 2. A semi-thin resin section of sural nerve showing onion bulb formations, some having demyelinated or thinly myelinated axons at their centre. Methylene blue, azure II, basic fuchsin (×570).

 longitudinal semithin sections examined by light microscopy (Fig. 9B) the outpouchings were seen to occur in multiple restricted areas which were both paranodal and internodal.

Fig. 6 Case 2. An electron micrograph of a transverse section of sural nerve showing a thinly myelinated axon surrounded by Schwann-cell processes enclosing an occasional axon (arrows). The innermost processes consist only of paired basement membranes (×300).

d type III HMSN or the Dejerine–Sottas syndrome, probably inherited as an autosomal recessive trait. It was characterized by relatively stereotyped clinical, electrophysiological and neuropathological findings and a generally uniform clinical course. Typically, developmental motor milestones were delayed, nerve conduction velocity was severely reduced and the peripheral nerves were enlarged. Pathologically, there was a

Discussion

Dyck (1975) and Dyck et al. (1993) separated hypertrophic neuropathy of infancy as a distinct condition, designated as
normal parents. The clinical features in the present series are summarized in Table 2. Cases 1–7 conformed to the HMSN III phenotype, apart from a mother and son both being affected (Cases 3 and 4). Onset was in infancy, nerve conduction velocity was markedly reduced or the peripheral nerves were totally inexcitable, and progression to severe disability occurred. The pattern of neurological involvement was similar in all cases, although severity varied. It was particularly severe in Case 9 who displayed bulbar involvement. A feature that differed from the description given by Dyck et al. (1993) was the lack of nerve thickening, although enlarged spinal roots were observed on myelography in Case 4. From their clinical features it would not have been possible to have predicted the underlying genetic defect. Gabréëls-Festen and Gabréëls (1993) emphasized that childhood chronic inflammatory demyelinating polyneuropathy can mimic HMSN III very closely. In the present series, Case 8 was originally referred to us as a possible instance of chronic inflammatory demyelinating polyneuropathy because of the electrophysiological finding of conduction block which was not confirmed in our own studies.

Cases 1, 4 and 9 displayed diaphragmatic weakness. This is known to occur in HMSN, both in types I and II (Hardie et al., 1990) and phrenic nerve involvement has been described in Dejerine–Sottas disease (Felice et al., 1994). Case 9 also showed involvement of the laryngeal muscles. This is not surprising for severely affected individuals with a length-related neuropathy, in view of the length of the phrenic and recurrent laryngeal nerves. Two patients developed deafness (Cases 1 and 7), although whether this was part of the HMSN is uncertain. Deafness may occur in HMSN, either on its own (Satya-Murti et al., 1979) or in conjunction with optic atrophy (Rosenberg and Chutorian, 1967). None of our cases showed visual loss.

Cases 1–4 in the present series were found to have missense mutations in the PMP22 gene. In all, these were novel mutations. There have now been a number of reports of mutations in the PMP22 gene in individuals without a chromosome 17p11.2 duplication. Nicholson et al. (1994) reported an individual with hereditary neuropathy with liability to pressure palsies (HNPP) who showed a 2 bp deletion, occurring at amino acid 7, resulting in a frame shift and a premature termination. This presumably acted as a null mutation and therefore had the same effect as a segmental deletion of chromosome 17p11.2 duplication which is known to result in HNPP (Chance et al., 1993). Nelis et al. (1994b) reported a splice mutation comprising a G→A change at the first nucleotide of intron 3. It was not possible to carry out mRNA studies and it is therefore uncertain whether a mutant protein was produced, possibly with a skipped exon, or whether a reduced amount of normal protein was produced. The patient was diagnosed as having HMSN I and had an MNCV of 18 m/s. In a Dutch kindred in which the symptoms were severe (Hoogendijk et al., 1993) and in which most of the affected individuals would have been given a diagnosis of HMSN III, there was a leucine→proline mutation in amino acid 16, predicted to lie in the first transmembrane domain. Of
the six other missense mutations reported to date (Roa et al., 1993a–c; Ionasescu et al., 1995; Valentijn et al., 1995), Thr118Met was found in a unique family in which recessive inheritance was uncovered by cosegregation with a 1.5 Mb deletion (Roa et al., 1993b) and the remainder were described either as phenotypically type I (Ser79Cys; Roa et al., 1993c) or type III (His12Glu, Met69Lys, Ser72Leu; Roa et al., 1993a; Ionasescu et al., 1995; Valentijn et al., 1995).

Fig. 8 Case 7. Transverse electron micrographs of sural nerve. (A) A myelinated axon surrounded by a zone of collagen fibrils, within which there are a few concentrically arranged Schwann cell processes (s) and fibroblasts (f). (B) A myelinated axon surrounded by multiple layers of fragmented basal lamina (bl). (C) A myelinated axon surrounded by a dense collagenous zone the inner part of which contains multiple layers of partially fragmented basal lamina (arrow). (D) An axon (ax) surrounded by a noncompacted spiral mesaxon. The associated Schwann cell contains multiple dense bodies. Bars = 1µm.
Fig. 9 Case 8. (A) A transverse semi-thin section showing reduced myelinated fibre density. Some fibres possess highly contorted myelin sheaths (arrows). (B) A longitudinal semi-thin section. The myelinated fibres possess thin myelin sheaths which are frequently expanded into focal irregular zones (arrowed). Bars = 20 µm.

At least 17 point mutations have been described for the P0 gene. These have largely been missense mutations within exons 2 and 3 (Hayasaka et al., 1993a–c; Kulkens et al., 1993; Mitsui et al., 1994; Ohnishi et al., 1994; Rautenstrauss et al., 1994; Latour et al., 1995) but include two non-sense mutations in exon 6 (Hoogendijk et al., 1993). It is not clear how the complex mutation found in our Case 6, involving both a G→C change and a deletion within 4 bp, could have arisen. A frame shift occurs but, surprisingly, no termination codon is created until two amino acids beyond the normal termination codon. In its effect on protein structure, this is similar to a read through mutation previously described (Rautenstrauss et al., 1994) which resulted from a 2 bp insertion at amino acid 222 in exon 6. This case was also defined clinically as HMSN III.

How mutations affecting the PMP22 and P0 genes result in increased myelin thickness relative to axon diameter. This may well be a gene dosage effect (see Introduction). Patients with point mutations in the PMP22 gene had extremely high g ratios, indicating hypomyelination. Hypertrophic onion-bulb change was profuse from an early age in such cases whereas this developed more gradually in the duplication cases. Nerve biopsies from our Cases 1 and 2, both with PMP22 point mutations affecting the P0 gene. These have largely been missense mutations within exons 2 and 3 (Hayasaka et al., 1993a–c; Kulkens et al., 1993; Mitsui et al., 1994; Ohnishi et al., 1994; Rautenstrauss et al., 1994; Latour et al., 1995) but include two non-sense mutations in exon 6 (Hoogendijk et al., 1993). It is not clear how the complex mutation found in our Case 6, involving both a G→C change and a deletion within 4 bp, could have arisen. A frame shift occurs but, surprisingly, no termination codon is created until two amino acids beyond the normal termination codon. In its effect on protein structure, this is similar to a read through mutation previously described (Rautenstrauss et al., 1994) which resulted from a 2 bp insertion at amino acid 222 in exon 6. This case was also defined clinically as HMSN III.

How mutations affecting the PMP22 and P0 genes result in increased myelin thickness relative to axon diameter. This may well be a gene dosage effect (see Introduction). Patients with point mutations in the PMP22 gene had extremely high g ratios, indicating hypomyelination. Hypertrophic onion-bulb change was profuse from an early age in such cases whereas this developed more gradually in the duplication cases. Nerve biopsies from our Cases 1 and 2, both with PMP22 point mutations affecting the P0 gene. These have largely been missense mutations within exons 2 and 3 (Hayasaka et al., 1993a–c; Kulkens et al., 1993; Mitsui et al., 1994; Ohnishi et al., 1994; Rautenstrauss et al., 1994; Latour et al., 1995) but include two non-sense mutations in exon 6 (Hoogendijk et al., 1993). It is not clear how the complex mutation found in our Case 6, involving both a G→C change and a deletion within 4 bp, could have arisen. A frame shift occurs but, surprisingly, no termination codon is created until two amino acids beyond the normal termination codon. In its effect on protein structure, this is similar to a read through mutation previously described (Rautenstrauss et al., 1994) which resulted from a 2 bp insertion at amino acid 222 in exon 6. This case was also defined clinically as HMSN III.

How mutations affecting the PMP22 and P0 genes result in increased myelin thickness relative to axon diameter. This may well be a gene dosage effect (see Introduction). Patients with point mutations in the PMP22 gene had extremely high g ratios, indicating hypomyelination. Hypertrophic onion-bulb change was profuse from an early age in such cases whereas this developed more gradually in the duplication cases. Nerve biopsies from our Cases 1 and 2, both with PMP22 point mutations affecting the P0 gene. These have largely been missense mutations within exons 2 and 3 (Hayasaka et al., 1993a–c; Kulkens et al., 1993; Mitsui et al., 1994; Ohnishi et al., 1994; Rautenstrauss et al., 1994; Latour et al., 1995) but include two non-sense mutations in exon 6 (Hoogendijk et al., 1993). It is not clear how the complex mutation found in our Case 6, involving both a G→C change and a deletion within 4 bp, could have arisen. A frame shift occurs but, surprisingly, no termination codon is created until two amino acids beyond the normal termination codon. In its effect on protein structure, this is similar to a read through mutation previously described (Rautenstrauss et al., 1994) which resulted from a 2 bp insertion at amino acid 222 in exon 6. This case was also defined clinically as HMSN III.

How mutations affecting the PMP22 and P0 genes result in increased myelin thickness relative to axon diameter. This may well be a gene dosage effect (see Introduction). Patients with point mutations in the PMP22 gene had extremely high g ratios, indicating hypomyelination. Hypertrophic onion-bulb change was profuse from an early age in such cases whereas this developed more gradually in the duplication cases. Nerve biopsies from our Cases 1 and 2, both with PMP22 point mutations affecting the P0 gene. These have largely been missense mutations within exons 2 and 3 (Hayasaka et al., 1993a–c; Kulkens et al., 1993; Mitsui et al., 1994; Ohnishi et al., 1994; Rautenstrauss et al., 1994; Latour et al., 1995) but include two non-sense mutations in exon 6 (Hoogendijk et al., 1993). It is not clear how the complex mutation found in our Case 6, involving both a G→C change and a deletion within 4 bp, could have arisen. A frame shift occurs but, surprisingly, no termination codon is created until two amino acids beyond the normal termination codon. In its effect on protein structure, this is similar to a read through mutation previously described (Rautenstrauss et al., 1994) which resulted from a 2 bp insertion at amino acid 222 in exon 6. This case was also defined clinically as HMSN III.

How mutations affecting the PMP22 and P0 genes result in increased myelin thickness relative to axon diameter. This may well be a gene dosage effect (see Introduction). Patients with point mutations in the PMP22 gene had extremely high g ratios, indicating hypomyelination. Hypertrophic onion-bulb change was profuse from an early age in such cases whereas this developed more gradually in the duplication cases. Nerve biopsies from our Cases 1 and 2, both with PMP22 point mutations affecting the P0 gene. These have largely been missense mutations within exons 2 and 3 (Hayasaka et al., 1993a–c; Kulkens et al., 1993; Mitsui et al., 1994; Ohnishi et al., 1994; Rautenstrauss et al., 1994; Latour et al., 1995) but include two non-sense mutations in exon 6 (Hoogendijk et al., 1993). It is not clear how the complex mutation found in our Case 6, involving both a G→C change and a deletion within 4 bp, could have arisen. A frame shift occurs but, surprisingly, no termination codon is created until two amino acids beyond the normal termination codon. In its effect on protein structure, this is similar to a read through mutation previously described (Rautenstrauss et al., 1994) which resulted from a 2 bp insertion at amino acid 222 in exon 6. This case was also defined clinically as HMSN III.

How mutations affecting the PMP22 and P0 genes result in increased myelin thickness relative to axon diameter. This may well be a gene dosage effect (see Introduction). Patients with point mutations in the PMP22 gene had extremely high g ratios, indicating hypomyelination. Hypertrophic onion-bulb change was profuse from an early age in such cases whereas this developed more gradually in the duplication cases. Nerve biopsies from our Cases 1 and 2, both with PMP22 point mutations affecting the P0 gene. These have largely been missense mutations within exons 2 and 3 (Hayasaka et al., 1993a–c; Kulkens et al., 1993; Mitsui et al., 1994; Ohnishi et al., 1994; Rautenstrauss et al., 1994; Latour et al., 1995) but include two non-sense mutations in exon 6 (Hoogendijk et al., 1993). It is not clear how the complex mutation found in our Case 6, involving both a G→C change and a deletion within 4 bp, could have arisen. A frame shift occurs but, surprisingly, no termination codon is created until two amino acids beyond the normal termination codon. In its effect on protein structure, this is similar to a read through mutation previously described (Rautenstrauss et al., 1994) which resulted from a 2 bp insertion at amino acid 222 in exon 6. This case was also defined clinically as HMSN III.

How mutations affecting the PMP22 and P0 genes result in increased myelin thickness relative to axon diameter. This may well be a gene dosage effect (see Introduction). Patients with point mutations in the PMP22 gene had extremely high g ratios, indicating hypomyelination. Hypertrophic onion-bulb change was profuse from an early age in such cases whereas this developed more gradually in the duplication cases. Nerve biopsies from our Cases 1 and 2, both with PMP22 point mutations affecting the P0 gene. These have largely been missense mutations within exons 2 and 3 (Hayasaka et al., 1993a–c; Kulkens et al., 1993; Mitsui et al., 1994; Ohnishi et al., 1994; Rautenstrauss et al., 1994; Latour et al., 1995) but include two non-sense mutations in exon 6 (Hoogendijk et al., 1993). It is not clear how the complex mutation found in our Case 6, involving both a G→C change and a deletion within 4 bp, could have arisen. A frame shift occurs but, surprisingly, no termination codon is created until two amino acids beyond the normal termination codon. In its effect on protein structure, this is similar to a read through mutation previously described (Rautenstrauss et al., 1994) which resulted from a 2 bp insertion at amino acid 222 in exon 6. This case was also defined clinically as HMSN III.

How mutations affecting the PMP22 and P0 genes result in increased myelin thickness relative to axon diameter. This may well be a gene dosage effect (see Introduction). Patients with point mutations in the PMP22 gene had extremely high g ratios, indicating hypomyelination. Hypertrophic onion-bulb change was profuse from an early age in such cases whereas this developed more gradually in the duplication cases. Nerve biopsies from our Cases 1 and 2, both with PMP22 point
mutations, were hypomyelinated. Case 2 showed florid hypertrophic changes whereas they were not seen in Case 1 (although this biopsy specimen was not processed by contemporary morphological techniques). Nevertheless, this indicates that a uniform type of pathology may not be expected in patients with PMP22 point mutations. In our Case 6 with a P0 point mutation, intramuscular nerve fibres lacked detectable myelin sheaths, and only minor hypertrophic changes were evident.

Cases 7–9 are likely to be of autosomal recessive inheritance. In Case 7 there was close (father/daughter) parental consanguinity. In Cases 8 and 9 the parents were cousins. No
Table 2  Summary of cases presented

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (years)/sex</th>
<th>Inheritance</th>
<th>Genetic defect</th>
<th>Clinical features</th>
<th>MNCV (m/s)</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>39/F</td>
<td>AD*</td>
<td>PMP22 mutation</td>
<td>Neonatal hypotonia</td>
<td>Severe sensorimotor neuropathy; deafness</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>21/F</td>
<td>AD</td>
<td>PMP22 mutation</td>
<td>Delayed motor development</td>
<td>Severe sensorimotor neuropathy</td>
<td>Nerves inexcitable ND</td>
</tr>
<tr>
<td>3</td>
<td>2/M</td>
<td>AD</td>
<td>PMP22 mutation</td>
<td>Delayed motor development</td>
<td>Distal neuropathy</td>
<td>ND</td>
</tr>
<tr>
<td>4</td>
<td>28/F</td>
<td>AD*</td>
<td>PMP22 mutation</td>
<td>Neonatal hypotonia</td>
<td>Severe sensorimotor neuropathy; kyphoscoliosis; pes equinovarus</td>
<td>ND</td>
</tr>
<tr>
<td>5</td>
<td>6/F</td>
<td>AD*</td>
<td>P0 mutation</td>
<td>Delayed motor development</td>
<td>Severe sensorimotor neuropathy</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>25/F</td>
<td>AD*</td>
<td>P0 mutation</td>
<td>Delayed motor development</td>
<td>Severe sensorimotor neuropathy</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>42/F</td>
<td>AR</td>
<td>Not known</td>
<td>Leg weakness from age 3 years</td>
<td>Severe sensorimotor neuropathy; kyphoscoliosis</td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>5/M</td>
<td>AR</td>
<td>Not known</td>
<td>Abnormal gait from age 1 year</td>
<td>Severe sensorimotor neuropathy</td>
<td>15</td>
</tr>
<tr>
<td>9</td>
<td>16/M</td>
<td>AR</td>
<td>Not known</td>
<td>Abnormal cry from birth; leg weakness from 13 months</td>
<td>Severe sensorimotor neuropathy; facial, bulbar and diaphragmatic weakness</td>
<td>16</td>
</tr>
</tbody>
</table>

MNCV = motor nerve conduction velocity; AD = autosomal dominant; AR = autosomal recessive (presumed); ND = not done. *Presumed de novo mutation.

abnormality was detected on sequencing the PMP22 and P0 genes in Case 7 and the disorder is thus likely to be related to a mutation at another unidentified locus. In recessively inherited Tunisian kindreds with a demyelinating neuropathy, the disorder was localized by homozygosity mapping to chromosome 8q23 (Ben Othmane et al., 1993). Both in those cases and in our Case 7, basal laminal onion bulbs were observed. Such onion bulbs, originally described by Lyon (1969), consist of double layers of basal laminae, arranged concentrically around a central axon, from which the Schwann cell processes have presumably disappeared. Our Case 7 differs materially from those of Ben Othmane et al. (1993) in that MNCV was severely reduced from an early age, whereas in the Tunisian patients mean MNCV was substantially faster at 29 m/s. They are thus likely to represent different conditions.

In three patients with congenital hypomyelination neuropathy with basal laminal onion bulbs, Sawaishi et al. (1995) undertook immunohistochemical studies on peripheral nerve for myelin basic protein and P0 and P2 myelin proteins. They found no differences from controls in myelin basic protein and P0, but P2 staining was severely reduced. The P2 protein gene was sequenced but found to be normal. It was therefore considered that the reduced P2 expression could be a secondary phenomenon. It was not stated whether mutation of the PMP22 or P0 genes had been excluded.

Patients diagnosed as having HMSN I with autosomal recessive inheritance are more severely affected than those with autosomal dominant HMSN I (Harding and Thomas, 1980c). Such cases may display basal laminal onion bulbs (Gabreëls-Festen et al., 1992). Others may show classical onion bulbs with concentrically proliferated Schwann cells in association with hypomyelination, as in the two siblings reported by Harding and Thomas (1980c) and Thomas et al. (1996).

The histology in our Cases 8 and 9 was characteristic of hereditary neuropathy with focally folded myelin sheaths (HNFFM) (Ohnishi et al., 1989; Gabreëls-Festen et al., 1990). Reported cases so far, like ours, have been of presumed autosomal recessive inheritance, although there is one report of this histological pattern in a dominantly inherited kinship (Umehara et al., 1993).

The classification of the hereditary motor and sensory neuropathies will need revision. As stated in the Introduction, the designation HMSN was introduced as a temporary expedience until such time as specific genetic defects could be identified. This is progressively taking place. The distinction between autosomal recessive HMSN I and HMSN III (or Dejerine–Sottas disease) is artificial, and mutational screening for PMP22 and P0 genes is advisable in any case with demyelinating neuropathy without a chromosome 17p11.2 duplication, which is more severe than usual and in which a genetic basis seems probable. For clinical purposes, such cases...
perhaps should now simply be referred to as hereditary
demyelinating neuropathies, specified by the nature of the
genetic defect or chromosomal linkage if established. Infantile
demyelinating neuropathy is seen to be genetically
complex. It can result from mutations of the PMP22 or P0 genes
or of genes at other unidentified loci. The histological features
of HNFFM are characteristic, but the gene or genes responsible
for this phenotype have not yet been located. A demyelinating
neuropathy with an onset in infancy can also occur in
metachromatic leukodystrophy (De Silva and Pearce, 1973)
and Niemann–Pick disease (Landrieu and Said, 1984). The
onset of classical Refsum’s disease in infancy has not been
documented and infantile Refsum’s disease does not give rise
to a demyelinating neuropathy.

The nature of examples of congenital neuropathy with
amyelination (Karch and Urich, 1975; Kennedy et al., 1977)
is still uncertain. These present with severe hypotonia at birth
or arthrogryposis (Charnas et al., 1988) and survival is limited.
It will be of interest to examine the PMP22 and P0 genes in
such cases.

Acknowledgements
We wish to thank Jennie Small and Jane Workman for technical
assistance, Joke de Vocht and Christine van Broeckhoven for
instruction in the SSCP analysis of P0, Kieran Price for
secretarial assistance, Neva Haites and Chris Bennett for
referring patients and Dr C. Clark for providing information
about Case 5. This study was supported by the Muscular
Dystrophy Group of Great Britain and Northern Ireland, and
by the Wellcome, Leverhulme and John and Barbara
Attenborough Trusts.

References
Ben Othmane K, Henriette F, Lennon F, Ben Hamida C, Blel S, Roses
AD, et al. Linkage of a locus (CMT 4A) for autosomal recessive
Charcot-Marie-Tooth disease to chromosome 8q. Hum Mol Genet

Chance PF, Bird TD, Matsunami N, Lensch MW, Brothman AR,
Feldman GM. Trisomy 17p associated with Charcot-Marie-Tooth
neuropathy type 1A phenotype: evidence for gene dosage as a

Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N,
Smith B, et al. DNA deletion associated with hereditary neuropathy

Chance PF, Abbas N, Lensch MW, Pentao L, Roa BB, Patel PI, et al.
Two autosomal dominant neuropathies result from reciprocal DNA
duplication/deletion of a region on chromosome 17. Hum Mol Genet

Charnas L, Trapp B, Griffin J. Congenital absence of peripheral
myelin: abnormal Schwann cell development causes lethal

Dejerine J, Sottas J. Sur la n´evrite interstitielle, hypertrophique et

De Silva KL, Pearce J. Neuropathy of metachromatic leucodystrophy.

Dyck PJ. Definition and basis of classification of hereditary
neuropathy with neuronal atrophy and degeneration. In: Dyck PJ,
Thomas PK, Lambert EH, editors. Peripheral neuropathy.

Dyck PJ, Lambert EH. Lower motor and primary sensory neuron
diseases with peroneal muscular atrophy. I. Neurologic, genetic, and
electrophysiologic findings in hereditary polyneuropathies. Arch
Neur 1968a; 18: 603–18.

Dyck PJ, Lambert EH. Lower motor and primary sensory neuron
diseases with peroneal muscular atrophy. II. Neurologic, genetic, and
electrophysiologic findings in various neuronal degenerations. Arch

Dyck PJ, Chance P, Lebo R, Carney JA. Hereditary motor and sensory
neuropathies. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo
JF, editors. Peripheral neuropathy. 3rd ed. Philadelphia: W.B.

Felice KJ, Fratkin JD, Feldman EL, Sima AA. Phrenic nerve
involvement in Dejerine-Sottas disease: a clinicopathological case

Gabreels-Festen AAAWM, Gabreels FJM. Hereditary demyelinating motor and

Gabreels-Festen AA, Gabreels FJ, Jennekens FGI, Janssen-van Kempen

Gabreels-Festen AA, Gabreels FJ, Jennekens FGI, Janssen-van Kempen
TW. Autosomal recessive form of hereditary
motor and sensory neuropathy type I. Neurology 1992; 42:
1755–61.

Gabreels-Festen AA, Gabreels FJ, Jennekens FGI, Janssen-van Kempen
TW. The status of HMSN type III. Neuros. Disord 1994; 4:
63–9.

Gabreels-Festen AA, Gabreels FJ, Jennekens FGI, Janssen-van Kempen
TW. The status of HMSN type II (neuronal type) and X-linked HMSN [Review]. Brain Pathol 1993;

Hallam PJ, Harding AE, Berciano J, Barker DF, Malcolm S.
Duplication of part of chromosome 17 is commonly associated with
hereditary motor and sensory neuropathy type I (Charcot-Marie-Tooth

Hanemann CO, Stoll G, D’Urso D, Fricke W, Martin JJ, Van
Broeckhoven C, et al. Peripheral myelin protein-22 expression in
Charcot-Marie-Tooth disease type 1A sural nerve biopsies. J Neurosci

Diaphragmatic weakness in hereditary motor and sensory neuropathy

Harding AE, Thomas PK. The clinical features of hereditary motor
and sensory neuropathy types I and II. Brain 1980a; 103: 259–80.

Hereditary demyelinating neuropathy of infancy 61


Hereditary demyelinating neuropathy of infancy


Received July 4, 1996. Revised August 13, 1996. Accepted August 23, 1996.